L1210 mouse leukemia cell lines resistant to mitomycin C (MMC) were established by repeated continuous exposure of parental L1210 leukemia cells to MMC in vitro. The established cell lines showed 13-fold or more resistance to MMC compared with the parental cell line. A macromolecular prodrug of MMC, MMC-dextran conjugate with cationic charge (MMC-Dcat.), and lipophilic MMC prodrugs were assessed for ability to circumvent the resistance of tumor cells against MMC. Association of MMC and its prodrugs with resistant cell lines was similar to that with the parental cell line. Higher cellular association of drugs was observed with increase of the molecular weight of MMC-D and with increase of the partition coefficient of lipophilic MMC prodrugs.
Introduction
Mitomycin C (MMC) is a highly active antitumor antibiotic in both animal tumor systems and a variety of human neoplastic diseases. Its utility in human therapy, however, has been limited primarily by severe cumulative myelosupression or gastrointestinal damage.1) These disadvantages could be overcome and the therapeutic efficacy enhanced if the cytotoxicity were localized at the tumor site and if the burden on other tissues could be minimized by improving the pharmacokinetic properties and cellular access of MMC.2) One possible approach is the chemical transformation of the drug molecule into a latent from (prodrug). 3) We have developed various kinds of derivatives of MMC by coupling it with polymer beads,4) polysaccharide,5) and polyamino acid,6) or by substituting la-N-position with lipophilic carrier groups. 7, 8) We have already reported their physicochemical,9,10) pharmacological, 11, 12) and pharmacokinetic characteristics. 13 -15) Cellular interaction characteristics and cytotoxicity of these prodrugs have been examined in parental L1210 leukemia and Ehrlich ascites carcinoma cells, in relation to the mode of action. 16, 17) Through these investigations, some prodrugs of MMC were proved to have excellent therapeutic efficacy due to improved pharmacokinetic properties.
Development of drug resistance in malignant cells during treatment is another major obstacle to cancer chemotherapy.") From the clinical viewpoint, the absolute sensitivity of tumor cells to an anticancer drug, i.e., the drug concentration required to kill tumor cells, is more important than the relative resistance compared with the parental cell line. Therefore, we have established MMC-resistant L1210 leukemia cell lines by continuous exposure of the parental L1210 cell line to MMC in vitro. We investigated the association of macromolecular prodrugs of MMC, cationic MMC-dextran conjugate (MMC-Drat.) with molecular weights of 10000, 70000, and 500000, and lipophilic MMC prodrugs having a benzylcarbonyl, benzyloxycarbonyl, or nonyloxycarbonyl group, with the resistant cells. Their growthinhibitory effects on MMC-resistant cells were compared with those on the parental MMCsensitive cells. The possibility of overcoming drug resistance of tumor cells by means of the prodrug approach is discussed.
Experimental

Materials
MMC was kindly supplied by Kyowa Hakko Kogyo Co. Cationic MMC-D with a molecular weight of 10000 (T-10), 70000 (T-70) or 500000 (T-500), and lipophilic MMC derivatives coupled with benzylcarbonyl, benzyloxycarbonyl or nonyloxycarbonyl groups were synthesized as described previously.w) All other chemicals were of reagent grade and were obtained commercially.
Cell Culture The growth medium for parental L1210 leukemia cell line and its MMC-resistant sublines was RPMI 1640 medium supplemented with 10% fetal bovine serum (Grand Island Biological Co., NY). The cells were maintained in the growth medium in tissue culture dishes (Becton, Dickinson and Co., CA) at 37 °C in a humidified atmosphere containing 5% CO2.
Establishment of L1210 Cell Lines Resistant to MMC Initial induction of resistance was achieved by continuous exposure of L1210 cells to a sublethal concentration of MMC (0.07 pg/m1) over 2 months. Medium change was carried out every 4-5 d. The concentration of MMC was gradually increased every 10 or more passages. During the culture, the cells were continuously exposed to MMC. After at least 10 passages with a certain concentration of MMC, cells were maintained in the growth medium without MMC. The degree of resistance, which was calculated as the ratio of IC50 (drug concentration giving 50% growth inhibition) of resistant cells to that of the parental cells, did not change over 6 months under these conditions. Obtained cell lines were named according to the final concentration of MMC; i.e., cell line M1 was established by cultivation with a final MMC concentration of 1 fig/ml. Cellular Interaction of MMC Prodrugs Tumor cells were suspended in. Hanks' balanced salt solution (106 cells/ml), concentrated drug solution was added to give a final concentration of 10 pg equivalent MMC/ml, and the mixture was incubated for a definite period at 37 °C. After centrifugation at 3000 rpm for 5 min, the drug concentration in the supernatant was measured spectroscopically and the association percentage was calculated.
Growth Inhibitory Effects of MMC Prodrugs with Continuous Exposure Parental or MMC-resistant L1210 leukemia cells were suspended in the growth medium, drug solution was added, and the mixture was seeded on a multiwell tissue culture plate (Becton, Dickinson and Co., CA) at a density of 105 cell/ml/well. After incubation in a humidified atmosphere containing 5% CO2 at 37 °C for 72 h, viable cells were counted with a Bfirker-Turk hemocytometer by the trypan blue exclusion method. The growth inhibition was calculted as follows: growth inhibition (%)= (1-T/C) x 100, where T and C represent the number of surviving cells in a treated group and that in an untreated control group, respectively. Experiments were carried out in triplicate.
Growth Inhibitory Effects of MMC Prodrugs with 1 h Exposure-Cells were exposed to various concentrations of drugs in Hanks' balanced salt solution buffered with 20 mm N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid for 1 h at 37 °C. Drug-treated cells were washed twice with the same medium, resuspended in the growth medium, and cultured for 96 h, and growth inhibition was determined as above.
Results
Characteristics of MMC Resistant L1210 Leukemia Cell Lines
The doubling times and drug sensitivities of MMC-resistant cell lines are summarized in Table I . The doubling time of the parental cell line was about 11 h and those of the resistant cell lines were slightly longer. The degree of resistance was calculated as the ratio of IC50 for a resistant cell line to that for the parental cell line. A resistant cell line Ml, which was finally exposed to 1 ,ug/ml of MMC, was approximately 14-fold more resistant to MMC as compared with the parental cell line. The extent of resistance to MMC increased with increase of the MMC concentration to which the cells were exposed during cultivation. MMC resistant cells also showed resistance to adriamycin, but the degree of resistance to adriamycin was smaller than that to MMC. The size and shape of the parental and resistant cells were almost the same as determined by microscopical observation. The cell lines which showed higher resistance were used for further study. B) Cells were exposed to various concentrations of MMC or MMC-Dcat . for 1 h in Hanks' balanced salt solution. After being washed twice with the same medium, cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum for 4 d. Growth inhibition percentage was determined as above.
interaction was observed with an increase of molecular weight of dextran in the case of macromolecular prodrugs (Fig. 1) . Nonyloxycarbonyl MMC, which has a highest partition coefficient in the chloroform/water system,19) showed the highest uptake among the tested lipophilic prodrugs (Fig. 2 ). No significant difference was observed between uptake percentages of MMC prodrugs by the parental cell line and those by the resistant cell lines. Figures 3 and 4 illustrate the growth-inhibitory effects of MMC-Dcat . and lipophilic MMC prodrugs, respectively, on an MMC-resistant L1210 cell line (M1). In the continuous exposure experiment (Figs. 3A and 4A) , prodrugs except for nonyloxycarbonyl MMC showed slightly lower activity than MMC against MMC-resistant cells.
Growth-Inhibitory Effects of MMC Prodrugs
In A) Growth inhibition was determined as described in the legend to Fig. 3(A) . B) Growth inhibition was determined as described in the legend to Fig. 3(B) . of 70000 or 500000 showed much higher cytotoxicity against the parental L1210 cells.') Among lipophilic prodrugs, nonyloxycarbonyl MMC exhibited higher growth-inhibitory activity than MMC against the MMC-resistant cell line as well as the parental cell line. A close relation between growth-inhibitory activity and cellular uptake of drug was also observed in the case of the resistant cell line.
In Tables II and III , the cytotoxic activities of MMC prodrugs against MMC-resistant L1210 leukemia cell lines are summarized in terms of IC50. In the continuous exposure experiments, MMC-resistant cell lines showed relatively similar resistances to MMC prodrugs and to MMC (Table II) . The degree of resistance to nonyloxycarbonyl MMC was somewhat lower than those to other agents. M1 and M1.5 showed higher resistance to MMC-Dcat . as compared with MMC in the 1 h exposure experiments. On the other hand, the degrees of resistance to lipophilic MMC prodrugs, especially nonyloxycarbonyl MMC, were much lower than that to MMC. The IC50 value of nonyloxycarbonyl MMC in MMC resistant cell lines remained at the same level as that of MMC with the parental cell line.
Discussion
In cancer chemotherapy, acquisition of resistance to antitumor agents by cancer cells is one of the most serious problems. It was reported that usual response rates to anticancer drugs were only about 35% and the sensitivities of tumor cells to agents which had been previously used for treatment of the patient were significantly decreased in human tumor clonogenic assay. 20, 21) Consequently, many attempts have been made to circumvent drug resistance of tumor cells. 22 24) The resistance of tumor cells to many antineoplastic agents, such as anthracyclines,25'26) methotrexate,27) and alkylating agents,28' 29) has been studied. The mechanisms of resistance were considered to involve alteration of the drug transport system in tumor cells (defective cellular accumulation),30, 31) gene amplification of a target enzyme,32) increase of cellular protective substances such as glutathione,33) etc. Concerning resistance to MMC, the mechanism of resistance in human colon cancer cell lines has been reported to involve a decrease in deoxyribonucleic acid (DNA) cross-link formation,34) but the details are still unknown. 35) In this study, we established MMC-resistant cell lines by in vitro continuous exposure of L1210 leukemia cells to MMC and assessed the possibility of overcoming the resistance to MMC by chemical modification of the drug molecule by using this system. The doubling times of resistant cell lines were slightly longer than that of the parental cell line (Table I) . The degree of resistance to MMC increased with increase in the concentration of MMC to which the cells had been exposed. The resistance to MMC was stably maintained for more than 6 months. In order to characterize MMC-resistant cell lines, we tested the sensitivity of one (M1) to adriamycin, whose mode of action is rather similar to that of MMC, and resistance to which has been well investigated. The established cell line was also resistant to adriamycin, though MMC-resistant human colon cancer cells were not') This result suggests that M1 has higher activity to repair damaged DNA, and this is responsible for the resistance. In fact, uptake of MMC by resistant cells was not different from that by parental cells.
The mode of action of each type of prodrug tested in this study was previously examined. 16'17) In this investigation, similar results were obtained for the MMC-resistant cell line. MMC-D with its positive charge was strongly adsorbed on the tumor cell surface by electrostatic interaction and an increase in the adsorbed amount of MMC-Dcat . with increase of molecular weight was obserbed ( Fig. 1) . Adsorption of MMC-Dcat . on tumor cells conforms to Langmuir's adsorption isotherm.16) After adsorption on a tumor cell surface, MMC-Dcat . releases intact MMC by chemical hydrolysis and the liberated MMC would exhibit cytotoxicity. On the other hand, lipophilic prodrugs were incorporated into tumor cells through partition equilibrium between, the medium and cellular lipid components (Fig.  2) . After incorporation, lipophilic prodrugs are converted to the parent drug, MMC, by enzymatic hydrolysis.171 Both types of prodrugs showed a correlation between cytotoxic activity and cellular interaction.
In continuous drug exposure experiments, prodrugs were less active than MMC against the resistant cell lines, and the degrees of resistance to prodrugs were almost the same as that to MMC (Table II ). In the 1 h exposure experiment, although MMC-Dcat. exhibited higher activity than MMC against the parental L1210 cells, it showed lower activity against MMC resistant cell lines, resulting in higher degrees of resistance (Table III) .
In order to inhibit the growth of MMC-resistant sublines, therefore, a higher concentration of MMC was required compared with that in the case of the parental L1210 cell line. The difference in association amounts between MMC-Dcat . and MMC was large at low drug concentrations, but it became smaller at a higher concentration where the association of MMC-Dcat . was saturated.16) Thus, prodrugs which show saturable uptake may not be desirable, if large amounts of MMC•are required to kill the tumor cells. On the other hand, nonyloxycarbonyl MMC, a lipophilic MMC prodrug, showed higher cytotoxic activity to MMC-resistant cells as well as to parental cells, indicating that chemical transformation could lead to circumvention of drug resistance in this case. From these results, it is suggested that the mode of cellular interaction is important in the manifestation of antitumor effects of prodrugs against drug-resistant cell lines. The reason why the degree of resistance to lipophilic MMC was smaller is not clear.
In vivo, MMC injected in the free form is rapidly cleared from the injection site and the body, and contact with tumor cells occurs for only a short time. The in vitro 1-h exposure experiment may refrect this. In this case, MMC prodrugs, especially nonyloxycarbonyl MMC, should interact rapidly and strongly with tumor cells, be retained sufficiently in tumor cells after repeated washing, and show higher growth inhibition even against MMC-resistant tumor cells.
In addition, since the limiting factor in the efficacy of MMC-Dcat. against the MMCresistant cells is saturation of cellular adsorption, MMC-Dcat. may be available to overcome resistance in cell lines which are more sensitive to MMC than L1210 leukemia. That is, if an MMC-resistant cell line would be damaged at an MMC concentration which is, of course, higher than that for the parental cell line but sufficiently lower than that corresponding to saturation of cellular adsorption of MMC-D cat ., MMC-Deat. should effectively kill them in the same manner as the parental L1210 cells.16) In general, L1210 leukemia is known to show lower sensitivity to MMC as compared with other cell lines."
The feasibility of circumvention of the drug resistance by chemical modification of drug molecules to prodrugs having higher affinity to tumor cells has been thus demonstrated.
